Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study
The Journal of Infectious Diseases · 18.02.2026 · 233 (2) · e342-e351
DOI: 10.1093/infdis/jiaf600 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 25.11.2025. Verfasst von C Alaimo und 7 weiteren Autor:innen. Beteiligte Einrichtung: LimmaTech Biologics AG, Schlieren, Switzerland. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Klebsiella Infections, Bacterial Vaccines, Immunogenicity, Vaccine. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LimmaTech Biologics, University College London for the serology.
Abstract (Originalsprache)
Background
Safe and effective vaccines are urgently needed to prevent Klebsiella pneumoniae infections. We assessed safety and immunogenicity of a tetravalent bioconjugate vaccine Kleb4V, containing O antigen-polysaccharides of K. pneumoniae serotypes (O1v1, O2a, O2afg and O3b).
Methods
In this observer-blind, randomized, placebo-controlled, phase I/II trial (ClinicalTrials.gov NCT04959344), 166 healthy adults (16 aged 18–40 and 150 aged 55–70 years) were enrolled and randomized to receive 2 intramuscular injections of Kleb4V (16 or 64 μg of total O antigen with or without adjuvant AS03) or placebo on days 1 and 57. While the primary outcome was safety, the secondary outcomes included vaccine antigen immunogenicity.
Results
Kleb4V was well tolerated, with most solicited and unsolicited AEs of mild to moderate intensity. Kleb4V was immunogenic for all four vaccine-serotypes at both doses. O1v1, O2a and O2afg specific IgG increased after the 1st vaccination and IgG persisted at six months after the second vaccination. For three of the four vaccine-serotypes, the AS03-adjuvanted formulations showed a superior immune response. O3b responses were reduced compared to the other vaccine antigens.
Conclusions
Kleb4V is the first K. pneumoniae conjugate vaccine candidate to reach clinical assessment. The Kleb4V bioconjugate was immunogenic and well tolerated in the target population of adults aged 55–70 years for the vaccine-serotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LimmaTech Biologics AG, Schlieren, Switzerland.
- Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
- Nuvisan, Neu-Ulm, Germany.
ORCID-Profile: R Lawrence, D Goldblatt
Förderung
- LimmaTech Biologics
- University College London for the serology
Zitieren
APA
Alaimo, C., Karaky, N., Lawrence, R., Bownes, E., Haffner, S., Kowarik, M., Goldblatt, D., & Martin, P. (2026). Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study. The Journal of Infectious Diseases, 233(2), e342-e351. https://doi.org/10.1093/infdis/jiaf600
Vancouver
Alaimo C, Karaky N, Lawrence R, Bownes E, Haffner S, Kowarik M, et al. Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study. The Journal of Infectious Diseases. 2026;233(2):e342-e351. doi:10.1093/infdis/jiaf600
BibTeX
@article{Alaimo2026,
author = {Alaimo, C and Karaky, N and Lawrence, R and Bownes, E and Haffner, S and Kowarik, M and Goldblatt, D and Martin, P},
title = {Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {233},
number = {2},
pages = {e342--e351},
doi = {10.1093/infdis/jiaf600}
}
EUVIMED